The recent safety update led Kyowa Kirin and Amgen to conclude potential risks may outweigh benefits for patient populations.

Two new cancer cases have prompted Kyowa Kirin to shutter all clinical studies of its investigational anti-OX40 monoclonal ...

Phase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234 in healthy volunteers and adults with moderate to severe atopic dermatitisARQ-234 is a potent ...

Atopic dermatitis (AD) is a chronic disease that affects an increasing number of children and adults. The skin is dry and irritated, and the itching can be so severe that it interferes with sleep and ...

ORLANDO, Fla. — In a phase 3 atopic dermatitis (AD) trial, rocatinlimab, a novel therapy that targets T cells expressing the OX40 receptor, showed efficacy on both coprimary and key secondary ...

Please provide your email address to receive an email when new articles are posted on . Rezpegaldesleukin is a first-in-class interleukin-2 receptor agonist that proliferates and activates regulatory ...

BALLERUP, Denmark--(BUSINESS WIRE)--NOT FOR UK USE – NOT INTENDED FOR UK MEDIA LEO Pharma A/S, a global leader in medical dermatology, today announced positive results from the Phase 2a Mechanism of ...

Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the discontinuation of all ongoing clinical trials for rocatinlimab, an ...

PHB-050 is currently in a Phase 1 clinical trial for food allergy. The ongoing trial is expected to generate key data on safety, pharmacokinetics and the potential to rapidly reduce circulating IgE ...

Ivarmacitinib Provides Relief in Atopic Dermatitis Study A phase 3 trial shows that ivarmacitinib improves symptoms in adults with moderate to severe atopic dermatitis compared with placebo. Medscape ...